CLINICAL TRIALS PROFILE FOR BRIMONIDINE TARTRATE; TIMOLOL MALEATE
✉ Email this page to a colleague
All Clinical Trials for BRIMONIDINE TARTRATE; TIMOLOL MALEATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00435058 ↗ | Visual Function Changes After Intraocular Pressure Reduction | Completed | University of Sao Paulo | N/A | 2005-09-01 | During the glaucomatous disease process, subpopulations of cells may be dead, damaged or healthy. Visual function changes could be observed due to a recovering of the suffering ganglion cells after the intraocular pressure reduction. This study aims at evaluating the correlation between intraocular pressure reduction and visual function changes in glaucoma patients after using antiglaucoma medications. |
| NCT00698945 ↗ | Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) | Completed | Bp Consulting, Inc | Phase 4 | 2008-06-01 | To assess the additional benefit of common adjunctive classes on the diurnal IOP curve in patients assessed as needing additional treatment to reach target intraocular pressure (IOP). To demonstrate superiority of IOP control with Istalol 0.5% QD compared to Brimonidine Tartrate 0.2% BID as adjunctive therapy in adults with uncontrolled IOP's (determined by P.I. based on target pressures) currently treated with Latanoprost 0.05% in the study eye(s). |
| NCT00811564 ↗ | An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects | Completed | Allergan | Phase 4 | 2008-12-01 | A three-month evaluation comparing the safety and efficacy of a fixed combination of 0.2% brimonidine tartrate/0.5% timolol maleate with that of latanoprost 0.005%, a prostaglandin analogue in glaucoma or ocular hypertension subjects |
| NCT00811850 ↗ | Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow | Completed | Allergan | Phase 4 | 2008-12-01 | A 10 week evaluation, crossover design study including a 3 week washout period between treatments, to determine the effects of Combigan® (fixed combination brimonidine tartrate 0.2%/timolol maleate 0.5%) and Cosopt® (fixed combination dorzolamide hydrochloride-timolol maleate ophthalmic solutions) on ocular blood flow as measured by retrobulbar blood flow. |
| NCT01284166 ↗ | Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Withdrawn | Allergan | Phase 3 | 2013-07-01 | This study will investigate the safety and efficacy of Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution in patients with glaucoma or ocular hypertension who have elevated IOP on dorzolamide hydrochloride/timolol maleate combination therapy. |
| NCT01987752 ↗ | Safety and Efficacy of Combigan® Ophthalmic Solution in Korea | Completed | Allergan | 2009-01-01 | This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Combigan® (brimonidine tartrate/timolol maleate) Ophthalmic Solution in patients with Open Angle Glaucoma or Ocular hypertension with insufficient response to local beta blockers treated as per standard of care in clinical practice. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Condition Name
Clinical Trial Locations for BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Trials by Country
Clinical Trial Progress for BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Clinical Trial Phase
Clinical Trial Sponsors for BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Sponsor Name
